4.5 Article

The Impact of Chronic Cough: A Cross-Sectional European Survey

Journal

LUNG
Volume 193, Issue 3, Pages 401-408

Publisher

SPRINGER
DOI: 10.1007/s00408-015-9701-2

Keywords

Chronic cough; Antitussive therapy; Survey; Quality of life; Management

Funding

  1. National Institute of Health Research
  2. Pneumacare
  3. Boehringer Ingelheim
  4. Cheisi Pharma
  5. Novartis Pharmaceuticals
  6. Orion Pharma UK
  7. Procter & Gamble Health Sciences
  8. Pfizer
  9. Pharmaxis
  10. Profile Pharma
  11. MPEX Pharmaceuticals
  12. PPD Development
  13. Almirall
  14. Seekacure
  15. Philips Home Healthcare Solutions
  16. Glenmark
  17. Harrison Clinical Research
  18. Janssen
  19. Gilead
  20. Bayer
  21. Astrazeneca
  22. Genentech
  23. Bionoria
  24. PRA International
  25. GlaxoSmithKline
  26. Allianz Global
  27. Guangzhou Institute of Respiratory Disease
  28. Cardiff Chest Federation
  29. British Pharmacological Society
  30. Italian Society of Respiratory Medicine
  31. Drug Information Association
  32. SRxA USA
  33. Association of Inhalation Toxicologists
  34. Ardmore Healthcare Limited
  35. Actelion
  36. Hellenic Society of Respiratory and Occupational Chest Diseases
  37. Primary Care respiratory Society UK
  38. TREAT Education USA
  39. National Health and Lung Institute

Ask authors/readers for more resources

Studies that investigate the impact of chronic cough have largely focused on patients attending secondary care. Our aim was to investigate the opinions of the wider general population across Europe. An internet survey was made available in 12 languages on the European Lung Foundation website, between January 2012 and April 2013. Of 1120 respondents from 29 different European countries, 67 % were female, mean age 51 years (SD 15), median cough duration 2-5 years. The majority of respondents reported cough impacted their quality of life, mood and ability to undertake activities. Despite 72 % of respondents having visited their doctor a parts per thousand yen3 times, only 53 % had received a diagnosis. Asthma was the most common diagnosis (23 %). Most respondents reported limited or no effectiveness of medications. 88 % of respondents reported that they would like more information to be available on chronic cough. Chronic cough has a negative impact on quality of life. Further work is needed to raise awareness, promote management strategies, develop effective treatments and consider the educational and support needs of patients with chronic cough.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available